Berra Yazar-Klosinski

Company: Lykos Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion | Moving the Gold Standard Beyond Subjective Mood Scales & Evaluating the Potential of Surrogate Endpoints 10:15 am

What are the right endpoints to use in indications, such as substance use disorder, where a defined mood scale is not clear? Critically evaluating the value of Hamilton and MADRS scales: are there different, more objective ways of tracking the severity of various psychological illnesses? Are we close to having a surrogate in psychiatry with…Read more

day: Conference Day 2 AM

Workshop C: Navigating Evolving Regulatory Hurdles in an Era of Growing Potential for Psychedelic Drug Approvals 1:00 pm

As psychedelic drug assets progress into late phase clinical studies, there are some critical questions at the forefront of everybody’s minds: What is the optimal amount of psychological support that is necessary from a regulatory perspective in clinical trials for psychedelics? What are regulatory agencies looking for in terms of higher quality evidence or more…Read more

day: Pre-Conf Day - C